Lorlatinib and Bevacizumab Activity in ALK-Rearranged Lung Cancers After Lorlatinib Progression. uri icon

Overview

publication date

  • November 2, 2020

Identity

PubMed Central ID

  • PMC7713518

Scopus Document Identifier

  • 85076397427

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-19-1104

PubMed ID

  • 33283131

Additional Document Info

volume

  • 4